Impel NeuroPharma said that the first subject has been dosed in a Phase 1 study of INP105 intranasal dry powder olanzapine, which the company is developing for the treatment of acute agitation in bipolar I disorder and schizophrenia.
The “SNAP 101” PK/PD trial will compare 3 doses of INP105 to 5 mg and 10 mg doses of intramuscular Zyprexa and to 10 mg of orally disintegrating Zyprexa Zydis in healthy volunteers.
Impel CEO Jon Congleton commented, “The evolution of mental healthcare options and treatments in the US is a priority, and there is a specific unmet need for optimal treatments that could address acute agitation. Our goal with INP105 is to provide an easy-to-administer, rapidly-acting medicine that addresses acute agitation with a therapy that can be used in both the hospital and home setting without an injection.”
Read the Impel NeuroPharma press release.
